Treating fear with immune modulators
Nature Neuroscience
May 26, 2014
Memory extinction-the fading of old memories-in mice can be enhanced using a pharmaceutical drug presently used to treat a remitting-relapsing form of multiple sclerosis. The findings, reported online this week in Nature Neuroscience, suggest that this drug could be used to treat post-traumatic stress disorder and other anxiety disorders, if the same finding holds in people.
The drug, fingolimod, consists of a small molecule which is administered in an inactive form and converted in the body into an activated version by an enzyme called sphingosine kinase. Once active, it helps to suppress the immune system, thus treating some cases of multiple sclerosis.
Sarah Spiegel and colleagues report that the activated form of fingolimod has a second molecular function, independent of the immune system. The drug can inhibit an enzyme called histone deacetylase, a key epigenetic enzyme that regulates global gene expression. When administered orally to mice, fingolimod crossed the blood-brain barrier. Spiegel and colleagues report that mice given fingolimod were faster at extinguishing previously acquired fear memories. This action was specific to the activated form of the drug, since mutant mice that lack the activating enzyme sphingosine kinase failed to show memory changes.
doi: 10.1038/nn.3728
Research highlights
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports
-
Jun 24
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
Jun 23
Scientific community: Women credited less than men in scientific paper authorshipNature
-
Jun 17
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
Jun 17
Conservation: Feral cats pushing critically endangered marsupial further towards extinctionScientific Reports
-
Jun 16
Microbiology: DNA analysis indicates origins of the Black DeathNature